Last Friday, the Australian shares ended higher for the first time in a week. The benchmark S&P/ASX200 index gained 7.5 points, or 0.19 per cent, to 3,899.6 points, and the broader All Ordinaries index advanced 7 points, or 0.18 per cent, at 3894.4 points.
On Friday, the Australian market closed higher, lifted by the news of a massive joint venture between mining giants BHP Billiton and Rio Tinto after Rio scrapped the takeover deal with Chinalco. The benchmark S&P/ASX200 index was up 36.6 points, or 0.93 per cent, at 3971.2, while the broader All Ordinaries index gained 36.5 points, or 0.93 per cent, to 3969.0 points. Today the local market could be hit by lower commodities prices.
The Australian share market closed lower with a broad-based selling off after Wall Street's tumble. The benchmark S&P/ASX200 index slumped 45.4 points, or 1.2 per cent, at 3755.7, while the broader All Ordinaries index lost 41.4 points, or 1.1 per cent, to 3753.9.
The Australian share market yesterday closed slightly higher with a good lead from Wall Street. The benchmark S&P/ASX200 index gained 12.7 points, or 0.3 per cent, at 3801.1, while the broader All Ordinaries index rose 13.7 points, or 0.4 per cent, to 3795.3. There was a sell-off in late trading as investors drew cash to participate ANZ's capital raising.
The Directors of Benitec Limited (ASX:BLT)(PINK:BNIKF) provide the following update on the US patent re-examination of the '099 Graham patent. CSIRO filed an appeal with the USPTO Board of Patent Appeals and Interferences on 22 May against the two remaining obviousness rejections. CSIRO appealed the decision of the Examiner mailed 26 November 2008, rejecting reexamined claims 4 to 7 and 10 to 28 in connection with the merged ex parte reexamination.
The Australian share market showed a quiet response to the federal budget and closed in thin trading on Wednesday. Meanwhile, a growing list of companies seeking capital raising also absorbed attention from investors. The benchmark S&P/ASX200 index fell 21.1 points, or 0.54 per cent, at 3856.1, while the broader All Ordinaries index dropped 21.1 points, or 0.55 per cent, to 3842.5.
Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), today announced positive three-month interim efficacy results from the first 20 patients enrolled in the Phase 2 heart failure trial of the proprietary allogeneic, or "off-the-shelf", adult stem cell product Revascor(TM).
